Gynecological and breast oncology encompasses specialized medical care for cancers affecting the female reproductive system and breast tissue. Treatment requires a highly individualized, multi-disciplinary approach combining advanced chemotherapy, targeted biological drugs, and hormonal therapies.
Specialized Female Oncology Care
Under the expertise of Dr. Amit Saklani (MBBS, MD, DM Medical Oncology) in Jalandhar, female oncology patients receive evidence-based protocols tailored to tumor stage, receptor status (ER/PR/HER2), and genetic biomarkers (BRCA1/BRCA2, HRD status).
Comprehensive Cancers Treated
Dr. Saklani manages the full spectrum of female solid tumors:
- Breast Cancer: Complete medical management including Neoadjuvant Chemotherapy (to shrink tumors prior to breast-conserving surgery), Adjuvant Chemotherapy, Targeted HER2 Inhibitors (Trastuzumab, Pertuzumab), and Endocrine / Hormone Therapies (Aromatase Inhibitors, Tamoxifen).
- Ovarian & Fallopian Tube Cancers: Platinum-based doublet chemotherapy (Carboplatin + Paclitaxel), intraperitoneal protocols, and maintenance PARP Inhibitor therapies (Olaparib, Niraparib) for BRCA-mutated or HRD-positive tumors.
- Cervical Cancer: Concurrent Chemoradiation regimens (Cisplatin sensitization), anti-angiogenic therapy (Bevacizumab), and immune checkpoint inhibitors for recurrent or advanced disease.
- Uterine & Endometrial Cancers: Adjuvant chemotherapy, progestin hormone therapy, and molecular targeted therapies for advanced or recurrent endometrial carcinoma.
- Vulvar & Vaginal Malignancies: Individualized chemotherapy and biological protocols.
BRCA Genetic Counseling & Hereditary Risk Assessment
Dr. Saklani offers germline BRCA1/BRCA2 genetic testing for patients with ovarian or early-onset breast cancer. Identifying inherited genetic mutations guides targeted PARP inhibitor therapy and helps assess hereditary risk for family members.
Advanced Treatment Modalities Delivered
- Precision Targeted Therapy: HER2-targeted agents, T-DM1, and PARP inhibitors for specific molecular targets.
- Immunotherapy Integration: PD-L1 immune checkpoint inhibitors for triple-negative breast cancer and recurrent cervical cancer.
- Hormone / Endocrine Therapy: Blocking estrogen and progesterone receptors driving hormone-sensitive breast and endometrial cancers.
- Supportive & Bone Health Management: Bisphosphonate and RANKL inhibitor therapies to protect bone density during hormone blockades.
Compassionate Care at Patel Hospital Jalandhar
All female oncology treatments are delivered in a private, supportive day-care setting at Patel Hospital, Civil Lines Jalandhar, backed by dedicated nursing care, side-effect management, and compassionate emotional support supervised by Dr. Amit Saklani.
